Cmv Clinical Trials
Here are the 6 most popular medical studies for cmv
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
Popular filter options for cmv trials
Chronic Lymphocytic Leukemia Clinical Trials
View 8 Chronic Lymphocytic Leukemia medical studies.
Virus Therapy
CMV-Specific T-Cells for Cytomegalovirus Infection
This trial looks at whether white blood cells from donors who have been exposed to cytomegalovirus can help treat patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
Virus Therapy
Letermovir for Preventing Infection in Blood Cancer Patients
This trial looks at whether letermovir can prevent cytomegalovirus reactivation in cancer patients being treated with alemtuzumab. Letermovir may help by blocking the virus from replicating and preventing infection.
Acute Lymphoblastic Leukemia Clinical Trials
View 7 Acute Lymphoblastic Leukemia medical studies.
Virus Therapy
CMV-Specific T-Cells for Cytomegalovirus Infection
This trial looks at whether white blood cells from donors who have been exposed to cytomegalovirus can help treat patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
Cmv Clinical Trials With No Placebo
View 48 cmv medical studies that do not have a placebo group.
Device
Transpulmonary pressure targeting device for Respiratory Distress Syndrome
The use of positive end-expiratory pressure (PEEP) has been shown to prevent the cycling end-expiratory collapse during mechanical ventilation and to maintain alveolar recruitment, keeping lung portions open, increasing the resting end-expiratory volume. On the other hand PEEP may also overdistend the already open lung, increasing stress and strain. Theoretically high frequency oscillatory ventilation (HFOV) could be considered an ideal strategy in patients with ARDS for the small tidal volumes, but the expected benefits have not been shown yet. PEEP and HFOV should be tailored on individual physiology. Assuming that the esophageal pressure is a good estimation of pleural pressure, transpulmonary pressure can be estimated by the difference between airway pressure and esophageal pressure (PL= Paw - Pes). A PL of 0 cmH2O at end-expiration should keep the airways open (even if distal zones are not certainly recruited) and a PL of 15 cmH2O should produce an overall increase of lung recruitment. The investigators want to determine whether the prevention of atelectrauma by setting PEEP and mPaw to obtain 0 cmH2O of transpulmonary pressure at end expiratory volume is less injurious than lung recruitment limiting tidal overdistension by setting PEEP and mPaw at a threshold of 15 cmH2O of transpulmonary pressure. The comparison between conventional ventilation with tidal volume of 6 ml/Kg and HFOV enables us to understand the role of different tidal volumes on preventing atelectrauma and inducing lung recruitment. The use of non-invasive bedside techniques such as lung ultrasound, electrical impedance tomography, and transthoracic echocardiography are becoming necessary in ICU and may allow us to distinguish between lung recruitment and tidal overdistension at different PEEP/mPaw settings, in order to limit pulmonary and hemodynamic complications during CMV and HFOV.
Virus Therapy
CMV-Specific T-Cells for Cytomegalovirus Infection
This trial looks at whether white blood cells from donors who have been exposed to cytomegalovirus can help treat patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
T-cell Therapy
Donor-Derived CMV-Specific T-Cells for CMV Infection
This trial is testing whether transfusions of T-cells can help treat CMV infection. T-cells are a type of white blood cell that helps protect the body from infection. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.
Behavioural Intervention
Dried Blood Spot Testing for Cytomegalovirus Detection in Transplant Recipients
This trial will assess whether self-collection of dried blood spots will improve compliance with weekly CMV testing for hematopoietic cell transplantation recipients who are at high risk for late CMV disease.
View More Cmv Trials
See another 25 medical studies focused on cmv.
Frequently Asked Questions
Introduction to cmv
What are the top hospitals conducting cmv research?
When it comes to the cutting-edge research and treatment of cytomegalovirus (CMV), leading hospitals across the United States are paving the way for advancements in this field. Located in Duarte, California, City of Hope Medical Center is at the forefront with eight ongoing CMV trials. This medical center is dedicated to finding innovative solutions for CMV, a common virus that can cause complications in immunocompromised individuals. While their all-time record may show zero completed trials, their commitment to pushing boundaries in CMV research is evident.
Meanwhile, Crossroads Clinical Research located in Victoria also joins the league by actively conducting three clinical trials focused on CMV. Despite not having any past completed studies listed, this hospital's dedication to investigating potential treatments and therapies for CMV demonstrates its commitment to improving patient outcomes.
In Boston, Dana-Farber Cancer Institute is making strides with three active clinical trials dedicated solely to combating CMV. As one of the premier cancer institutes worldwide, Dana-Farber recognizes that CMV can pose significant challenges for patients undergoing cancer treatment or those who have received organ transplants.
Nationwide Children's Hospital situated in Columbus shares a similar focus on understanding and treating CMV infections among young patients. With three ongoing clinical trials centered around this condition, they provide hope for children affected by this potentially harmful virus.
Lastly but certainly not least important; The esteemed Children's Hospital of Philadelphia located right within Philadelphia itself also contributes significantly towards tackling Cytomegalovirus (CM) through its own cluster containing a total count of active-three investigations.Furthermore no recorded investigation has been concluded yet however considering these efforts being made it surely paints an optimistic picture regarding future prospects
Through these collaborative efforts from top-tier hospitals across different states in America , there lies great potential toward developing improved strategies against cmv -strategies which will ultimately benefit countless individuals facing such health concerns nationwide
Which are the best cities for cmv clinical trials?
When it comes to CMV clinical trials, several cities are leading the way in research and development. Houston, Texas, stands out with 15 active trials investigating treatments like mRNA-1647 Dose A, HLA-matched VSTs, and Vaccine Group. Columbus, Ohio follows closely behind with 12 ongoing studies focused on Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes and other potential interventions. New york City also proves to be a hub for CMV research with 10 active trials exploring treatments such as Valganciclovir and Lung Transplant Recipients. Boston, Massachusetts offers another promising location for CMV clinical trials with 8 ongoing studies examining treatment options like PEP-CMV and Vaccine Group. Lastly, Duarte, California contributes to the advancement of CMV research through its participation in 8 active trials exploring innovative approaches including tetanus-CMV fusion peptide vaccine and Multipeptide CMV-Modified Vaccinia Ankara Vaccine. These cities provide individuals affected by CMV access to cutting-edge clinical trials that pave the way for improved care outcomes.
Which are the top treatments for cmv being explored in clinical trials?
In the realm of clinical trials for CMV treatment, a few notable contenders have emerged. One standout is Letermovir, which has been the subject of 29 all-time trials and is currently being explored in six active studies. Another promising option is Maribavir, with four ongoing trials and a total of 26 past investigations dedicated to its potential effectiveness against CMV. These treatments hold great promise in advancing our understanding and management of this complex viral infection.
What are the most recent clinical trials for cmv?
Exciting advancements are being made in the field of CMV treatment through recent clinical trials. One promising trial involves the use of innovative treatments such as CMV-specific CD19-CAR T cells and a triplex vaccine. This Phase 1 study, which became available on 9/13/2023, aims to explore their effectiveness for combating CMV infection. Another Phase 2 trial focuses on lung transplant recipients who are particularly vulnerable to CMV complications. This study, available from 9/1/2023, seeks to identify optimal treatment approaches specific to this patient population. Additionally, another Phase 2 trial called Cohort A is investigating potential therapeutic options for CMV infections. These studies offer hope for improved management and outcomes in individuals affected by CMV.
What cmv clinical trials were recently completed?
Three recent clinical trials have investigated potential treatments for cytomegalovirus (CMV). In September 2021, a trial sponsored by the National Institute of Allergy and Infectious Diseases evaluated the efficacy of an experimental CMV vaccine. Another trial conducted by Duke University Medical Center focused on testing a novel antiviral therapy against CMV in June 2021. Additionally, in January 2021, a trial led by the University of Alabama at Birmingham explored the use of adoptive T-cell therapy to target CMV infection. These studies signify important strides towards advancing our understanding and treatment options for this challenging viral infection.